Effectiveness and safety of mesenchymal stem cell secretomes in severe COVID-19
COVID-19
Enrolment: 40 · Results not recorded
Loading the evidence…
Biologic
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
COVID-19
Enrolment: 40 · Results not recorded
COVID-19 · Cytokine Storm
Enrolment: 48 · Results not recorded
Persistent Corneal Epithelial Defect
Enrolment: 24 · Results not recorded
Acute Respiratory Distress Syndrome
Enrolment: 15 · Results not recorded
Liver Cirrhosis
Enrolment: 54 · Results not recorded
Epilepsy · Drug Resistant Epilepsy
Enrolment: 54 · Results not recorded
Ischemic Stroke · Post-Stroke Cognitive Impairment
Enrolment: 70 · Results not recorded
Melasma
Enrolment: 34 · Results not recorded
Degenerative Disc Disease
Enrolment: 20 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Lateral fluid percussion traumatic brain injury
Secretome therapy significantly attenuated motor deficits and cerebral infarction, reduced neuronal loss and apoptosis, and increased VEGF-positive cells in the injured cortex.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.